Healthcare · Market Entry
Gulf market entry for a South Asian pharma company
Regulatory mappedDistributor shortlistFirst listings
View all case studies →
Our POV · 2026
India genomics and precision medicine market entry strategy
India's genomics and precision medicine market is emerging as one of the world's most significant – with the world's largest genetically diverse population providing unparalleled research potential, ICMR's Genome India Project sequencing 10,000 Indian genomes creating foundational genetic data, government investment in biotech creating research infrastructure, and oncology precision medicine adoption accelerating in India's private hospital sector. International genomics companies, next-generation sequencing businesses, liquid biopsy technology providers, pharmacogenomics platforms, and precision oncology technology companies are all evaluating India as a priority genomics market. GreyRadius helps genomics companies validate Indian clinical demand, navigate ICMR and CDSCO regulatory requirements, identify hospital and research partners, and raise capital.
Why now? India's Genome India Project completion is creating a reference genome for the Indian population – enabling precision medicine applications calibrated for Indian genetic diversity that international genomics companies can develop and commercialise. The oncology precision medicine market in India is growing at 35% annually as targeted therapy adoption expands among India's growing specialist oncologist community.
$3B
India genomics and precision medicine market by 2027
Growing at 35% annually as oncology adoption, genetic testing awareness, and ICMR genomic infrastructure all accelerate.
30+
Primary interviews per India genomics mandate
Indian oncologists, hospital CIOs, and ICMR research officials – every engagement grounded in direct primary research.
8 weeks
India genomics market entry strategy
AI-augmented ICMR regulatory mapping and clinical demand research delivers India genomics market entry strategies efficiently.
Market Intelligence
What the data says.
India's genomics and precision medicine market is projected to reach $3B by 2027 – growing at 35% annually as oncology adoption, genetic testing awareness, and ICMR research infrastructure all accelerate.
India's cancer burden is the world's third-largest – 1.4 million new cancer cases annually with growing oncologist adoption of precision medicine creating significant NGS and liquid biopsy demand.
Genome India Project has created India's first population-representative reference genome – enabling precision medicine tools calibrated for South Asian genetic variants that differ significantly from Western reference genomes.
India's pharma industry is investing in pharmacogenomics – Indian generics manufacturers seeking to develop personalised medicine products are creating genomics technology and platform demand.
Market Reality
What makes this market hard.
- ICMR and CDSCO genomic data regulations are evolving – India's biological data sovereignty requirements and genomic data export restrictions affect how international genomics companies can operate.
- Clinical adoption of precision medicine requires specialist champion development – Indian oncologists require peer-reviewed evidence specific to Indian patient populations before adopting precision medicine workflows.
- Price sensitivity significantly affects genomics testing adoption – Indian patient willingness to pay for genetic testing is 20–30% of equivalent Western pricing requiring volume-based commercial models.
- Genomic data infrastructure in India is fragmented – hospital LIS, EMR, and genomics data systems are not interoperable requiring significant integration investment for genomics platform companies.
Our Work
What we solve for clients.
If you recognise your situation below, we can help.
India genomics clinical demand validation
You need to validate Indian oncologist, hospital, and research institution demand for your genomics technology and what ICMR and CDSCO compliance requirements apply.
ICMR and CDSCO regulatory pathway for genomics
You need to understand genomic testing certification, biological sample handling regulations, and data sovereignty requirements for genomics in India.
India genomics hospital and research partner identification
You need cancer hospital clinical champions, ICMR research institute partners, and genomics diagnostic chain partners.
India genomics GTM strategy
You need a go-to-market plan covering oncology hospital procurement, diagnostic chain distribution, and research institution partnerships.
Raising capital for India genomics investment
You need a pitch book grounded in India genomics market data, Genome India Project opportunity, and oncology demand analysis.
Indian population genomics adaptation strategy
You need a strategy for adapting your genomics technology to Indian population genetic variants rather than relying solely on Western reference genomes.
Our Services
How we engage.
Every engagement is grounded in primary research and delivers a measurable outcome.
Validate Indian oncologist and hospital demand for your genomics technology with clinical research and ICMR regulatory mapping.
Full financial feasibility for India genomics investment covering ICMR compliance and clinical adoption economics.
End-to-end India genomics market entry including regulatory pathway, hospital clinical champion identification, and first-clinical-deployment milestone.
Embedded India genomics GTM team covering oncology hospital and research institute outreach.
Investor-ready pitch books for India genomics investment with Genome India and precision oncology narrative.
AI use-case identification – from AI genomic interpretation calibrated for Indian population variants to automated pharmacogenomics advisory for Indian prescribers.
Why GreyRadius.
Primary research-led
80% of our insight comes from first-party interviews with buyers, competitors, and regulators – not secondary data that everyone else has.
Expert-led, AI-enabled delivery
Our AI layer compresses research timelines by 60% and surfaces pattern-matching from 200+ prior mandates – so you get faster, deeper answers.
Outcomes, not reports
We measure success by first contracts signed, capital raised, and markets entered – not deliverables produced. Every mandate has a milestone.
200+
Projects delivered
100+
SaaS & tech clients
80%
Primary research-led
4
Countries / offices
Case Studies
Mandates we've run.
Healthcare · GTM Execution
GTM for a digital-health platform in Southeast Asia
Clinic partnershipsB2B pipelineFirst ARR
View all case studies →
Healthcare · Assessment
Opportunity assessment for a medical-device launch in India
Clinical interviewsRegulatory reviewRevenue model
View all case studies →
FAQ
Common questions.
Does GreyRadius work with NGS companies or also with liquid biopsy, pharmacogenomics, and genetic counselling platform companies entering India?+
All genomics categories.
How long does an India genomics market entry engagement take?+
Typically 8–12 weeks for clinical demand research, ICMR regulatory mapping, and hospital partner identification.
Can GreyRadius identify Indian oncology clinical champion hospitals for genomics companies?+
Yes – oncology clinical champion hospital identification is core to our India genomics service.
How does India's Genome India Project affect genomics market entry strategy?+
Genome India creates Indian population reference data – we assess how your technology can be adapted for Indian genetic variants as part of every genomics engagement.
Stay informed
Market intelligence for Healthcare & Life Sciences leaders.
GreyRadius research notes, market entry signals, and sector briefs – delivered weekly. No fluff.
Not sure which engagement fits? Take our free 2-minute diagnostic →
Ready to enter this market?
Primary research. AI-enabled analysis, expert-reviewed. Outcomes-based delivery – across Gulf, Southeast Asia, South Asia.
Book a call